Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I SGM-101 intraoperative fluorescence imaging study in colorectal or pancreatic cancer
NL-OMON47359Phase 1Active, not recruiting
- Sponsor
- SurgiMab
- Start
- Jan 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sgm-101 in colorectal cancer (CRC) and pancreatic cancer (PC), sponsored by SurgiMab. Primary endpoint: Safety and tolerability. Started Jan 2016; status: active, not recruiting.
02
Drugs
sgm-101
03
Conditions
colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON47359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47359.